Product
Imatinib
Aliases
CGP 57148, CGP57148B, Gleevec, Glivec (5 other aliases)
Name
imatinib
Target
undefined
FDA Approved
Yes
Ema approved
Status
0
65 clinical trials
21 organizations
1 drug
1 abstract
80 indications
2 documents
Indication
GISTIndication
Chronic Myeloid LeukemiaIndication
Chronic PhaseIndication
Chronic Myelogenous LeukemiaIndication
LeukemiaIndication
MyelogenousIndication
ChronicIndication
BCR-ABL positiveIndication
dermoidIndication
Gastrointestinal stromal tumorIndication
Acute Lymphoblastic LeukemiaIndication
hematologic malignanciesIndication
Chronic Myeloid LeukaemiaIndication
Acute LymphoblasticIndication
Sickle Cell DiseaseIndication
Pulmonary Arterial HypertensionIndication
Chronic MyeloidIndication
Hematologic DisordersIndication
Malignant NeoplasmIndication
KITIndication
Stage IV Cutaneous MelanomaIndication
Metastatic Malignant Solid NeoplasmIndication
Metastatic MelanomaIndication
Cutaneous MelanomaIndication
melanomaIndication
Desmoid TumorIndication
ChondrosarcomaIndication
NeoplasmIndication
Eosinophilic Myeloid NeoplasmsIndication
Hypereosinophilic SyndromeIndication
SarcomaIndication
COVID-19Indication
Adult Acute Lymphoblastic LeukemiaIndication
Chronic Myeloid Leukemia (CML)Indication
TuberculosisIndication
Rare Malignant NeoplasmIndication
BCR-ABL1-positiveIndication
MRDIndication
Gastrointestinal Stromal Tumor (GIST)Indication
Head and Neck CancerIndication
Squamous Cell Carcinoma of Head and NeckIndication
malignantIndication
KIT MutationIndication
solid tumorIndication
Protocol SpecificIndication
Lymphoblastic LymphomaIndication
Ph+ ALLIndication
Metastatic CancerIndication
BCR/ABL-positiveIndication
Chronic Myeloid Leukemia in RemissionIndication
Gastrointestinal Stromal TumorsIndication
Non-metastaticIndication
high risk of recurrenceIndication
KIT gene mutationIndication
BCR-ABL1 PositiveIndication
Philadelphia Chromosome PositiveIndication
Melanoma stage IIIIndication
Pancreatic CancerIndication
AsthmaIndication
Philadelphia chromosomeIndication
Maximum Tolerated DoseIndication
Adult Soft Tissue SarcomaIndication
Drug ToxicityIndication
Substance Use DisorderIndication
myeloidIndication
Breast CancerIndication
Triple-Negative Breast CancerIndication
Papillary Thyroid CancerIndication
Mixed Phenotype Acute LeukemiaIndication
MucositisIndication
Oral ComplicationsIndication
Gastrointestinal Stromal Tumor of RectumIndication
WithdrawalIndication
Community-acquired PneumoniaIndication
InfluenzaDrug
ImatinibClinical trial
A Phase 1 Study of TAS-116 (Pimitespib) in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal TumorStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2023-03-03
Clinical trial
An Open Label, Multi-center Asciminib Roll-over Study to Assess Long-term Safety in Patients Who Have Completed a Novartis Sponsored Asciminib Study and Are Judged by the Investigator to Benefit From Continued TreatmentStatus: Recruiting, Estimated PCD: 2027-08-27
Clinical trial
A Phase II, Open-Label, Randomized, Controlled Study to Evaluate Efficacy and Safety of Vactosertib and Imatinib Combination in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis) Compared With Imatinib MonotherapyStatus: Recruiting, Estimated PCD: 2021-11-23
Clinical trial
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib TreatmentStatus: Active (not recruiting), Estimated PCD: 2033-04-21
Clinical trial
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)Status: Completed, Estimated PCD: 2021-06-03
Clinical trial
A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic MalignanciesStatus: Completed, Estimated PCD: 2018-12-14
Clinical trial
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, 2-parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-intestinal Stromal Tumor in First Line Medical TreatmentStatus: Terminated, Estimated PCD: 2018-07-01
Clinical trial
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Status: Active (not recruiting), Estimated PCD: 2022-08-12
Clinical trial
Retrospective, Non-interventional Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund DatabaseStatus: Completed, Estimated PCD: 2022-01-31
Clinical trial
A Dose Calibration and Dose Equivalence Pharmacokinetic Study in Healthy Volunteers Comparing IkT-001Pro to Imatinib Mesylate 400mgStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg ImatinibStatus: Completed, Estimated PCD: 2017-11-08
Abstract
Prior authorizations for oral anticancer drugs and delayed prescription fills.Org: Boston, MA, Harvard Medical School,
Clinical trial
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)Status: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
IMatinib for PAin in Chronic Treatment of Sickle Cell Anemia (IMPACT SCA): A Pilot Study of Imatinib in Patients With Sickle Cell Anemia and Recurrent Vaso-occlusive PainStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
Positioning Imatinib for Pulmonary Arterial HypertensionStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular ResponseStatus: Active (not recruiting), Estimated PCD: 2021-11-08
Clinical trial
A Phase 2 Study of Imatinib Therapeutic Drug Monitoring in Gastrointestinal Stromal TumorStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-12-13
Clinical trial
A Multicentre, Randomized Trial in Adults With de Novo Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia to Assess the Efficacy of Ponatinib Versus Imatinib in Combination With Low-intensity Chemotherapy, to Compare End of Therapy With Indication for SCT Versus TKI, Blinatumomab and Chemotherapy in Optimal Responders and to Evaluate Blinatumomab in Suboptimal Responders (GMALL-EVOLVE)Status: Recruiting, Estimated PCD: 2029-07-01
Clinical trial
Open-label Trial of Imatinib in Patients With Desmoid Tumor and ChondrosarcomaStatus: Completed, Estimated PCD: 2018-12-01
Clinical trial
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic SyndromeStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III StudyStatus: Active (not recruiting), Estimated PCD: 2026-05-01
Clinical trial
Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI DiscontinuationStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022)Status: Not yet recruiting, Estimated PCD: 2028-12-25
Clinical trial
A Multicentre, Open-label Phase II Trial Evaluating the Safety and Efficacy of Ponatinib Induction Followed by Imatinib Maintenance in Adult Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) ≤ 65 YearsStatus: Active (not recruiting), Estimated PCD: 2029-06-01
Clinical trial
IMPACT-TB (Imatinib Mesylate Per Oral as a Clinical Therapeutic for TB): A Phase II Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and RifabutinStatus: Completed, Estimated PCD: 2022-08-30
Clinical trial
The MATRIX Clinical Studies of Precision Cancer Therapy for Rare CancersStatus: Not yet recruiting, Estimated PCD: 2028-11-01
Clinical trial
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseStatus: Recruiting, Estimated PCD: 2028-08-31
Clinical trial
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill PatientsStatus: Recruiting, Estimated PCD: 2028-07-31
Clinical trial
KISS Study: A Phase II Study of Dasatinib Followed by Imatinib in Newly Diagnosed, Previously Untreated Patients With Chronic Phase CMLStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of DiseaseStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to Improve Risk Assignment in Childhood, Adolescent and Young Adult Acute Lymphoblastic LeukaemiaStatus: Recruiting, Estimated PCD: 2030-03-01
Clinical trial
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard TreatmentsStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Pilot Window of Opportunity Study of Imatinib in Combination With Cetuximab in Patients With Squamous Cell Carcinomas of the Head and NeckStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
ALL Adult Consortium Trial: Adult ALL TrialStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Entacapone in Combination With Imatinib Mesylate for Treatment of Patients With Gastrointestinal Stromal Tumors(GIST) Following Failure of at Least Imatinib and SunitinibStatus: Completed, Estimated PCD: 2022-08-31
Clinical trial
Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs)Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase I Study of Imatinib, Gemcitabine and Capecitabine in Patients With Solid TumorsStatus: Completed, Estimated PCD: 2009-01-30
Clinical trial
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL PatientsStatus: Active (not recruiting), Estimated PCD: 2022-08-01
Clinical trial
A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Imatinib Combined With Chemotherapy in Patients With Newly Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase II Multicenter Clinical Trial on Imatinib Treatment for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs)Status: Completed, Estimated PCD: 2016-03-01
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label, Trial Evaluating the Efficacy and Safety of Asciminib Used in Consolidation With Imatinib v. Imatinib to Achieve Treatment-free Remission in Chronic Phase-Chronic Myelogenous Leukemia PatientsStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2023-11-28
Clinical trial
A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)Status: Completed, Estimated PCD: 2023-12-01
Clinical trial
Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First RemissionStatus: , Estimated PCD: 2006-12-01
Clinical trial
Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsStatus: Terminated, Estimated PCD: 2019-09-24
Clinical trial
A Phase II Study of Binimetinib in Combination With Imatinib in Patients With Advanced KIT-Mutant MelanomaStatus: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
Phase II Study of Imatinib Mesylate and Gemcitabine for First-line Treatment of Metastatic Pancreatic CancerStatus: Completed, Estimated PCD: 2010-10-01
Clinical trial
Exploring the Molecular Mechanism of Secondary Resistance to Imatinib in Gastrointestinal Stromal Tumors Based on KIT MutationStatus: Recruiting, Estimated PCD: 2024-09-10
Clinical trial
PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network StudyStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Frontline Asciminib Combination in Chronic Phase CMLStatus: Active (not recruiting), Estimated PCD: 2027-12-01
Clinical trial
An Open-label, Phase II Study to Explore the Safety and Efficacy of Imatinib With Chemotherapy in Pediatric Patients With Ph+ / BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ALL)Status: Completed, Estimated PCD: 2016-03-30
Clinical trial
A Multicenter, Phase Ib/II Trial of Selinexor as a Single Agent and in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GISTs)Status: Active (not recruiting), Estimated PCD: 2023-04-16
Clinical trial
A Phase IIb Study of Molecular Responses to Imatinib, at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients With Chronic Myelogenous Leukemia (CML) in Chronic PhaseStatus: Active (not recruiting), Estimated PCD: 2010-11-01
Clinical trial
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)Status: Completed, Estimated PCD: 2021-04-06
Clinical trial
Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast CancerStatus: Not yet recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 2 Study of 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk of Recurrence Following Surgical ResectionStatus: Recruiting, Estimated PCD: 2030-04-30
Clinical trial
Randomized Phase II Trial of Gemcitabine and Imatinib Mesylate Versus Gemcitabine Alone in Patients With Previously Treated Locally Advanced or Metastatic Breast CancerStatus: Terminated, Estimated PCD: 2011-04-15
Clinical trial
A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer PatientsStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy BackbonesStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST: an Open-label, Single-arm, Phase III Trial（PIRKER）Status: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-step Dose Reduction in Patients With Chronic Myeloid Leukemia in Deep Molecular RemissionStatus: Active (not recruiting), Estimated PCD: 2026-06-01
Clinical trial
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaStatus: Recruiting, Estimated PCD: 2026-02-01
Organization
Sun Pharmaceutical Industries, Inc.Organization
Major PharmaceuticalsOrganization
Qilu Pharmaceutical Co., Ltd.Organization
Apotex Corp.Organization
Aurobindo Pharma LimitedOrganization
Amneal Pharmaceuticals LLCOrganization
Quallent Pharmaceuticals Health LLCOrganization
Teva Pharmaceuticals USA, Inc.Organization
Upsher-Smith Laboratories, LLCOrganization
Mylan Institutional Inc.Organization
Mylan Pharmaceuticals Inc.Organization
Zydus Pharmaceuticals USA Inc.Document
DailyMed Label: GleevecOrganization
Novartis Pharmaceuticals CorporationOrganization
Zydus Lifesciences LimitedOrganization
Archis Pharma LLCOrganization
BluePoint LaboratoriesOrganization
Golden State Medical Supply, Inc.Organization
Dr.Reddy's Laboratories IncOrganization
Chartwell RX, LLCOrganization
Apotex Corp Organization
American Health Packaging